Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vor Biopharma (VOR)
NASDAQ:VOR
Holding VOR?
Track your performance easily
VOR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.90 - $3.48
Previous Close$0.95
Volume163.51K
Average Volume (3M)356.25K
Market Cap
$64.85M
Enterprise Value-$36.67M
Total Cash (Recent Filing)$137.18M
Total Debt (Recent Filing)$35.66M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Aug 08, 2024EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.78
Shares Outstanding68,259,602
10 Day Avg. Volume259,990
30 Day Avg. Volume356,253
Standard Deviation0.18
R-Squared0.00648
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)0.47
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.30
Forecast
1Y Price Target
$14.36Price Target Upside1379.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Vor Biopharma News
PremiumCompany Announcements
Vor Biopharma Reports Q3 2024 Financial Results
PremiumCompany Announcements
Vor Biopharma Appoints New CFO, Enhances Leadership Team
PremiumCompany Announcements
Vor Biopharma Advances Innovative Blood Cancer TherapiesBulls Say, Bears Say
Bulls Say
Clinical TrialsThe likelihood of seeing clinical activity with a reasonable safety profile from VCAR33ALLO in relapsed/refractory acute myeloid leukemia is optimistic.
ExpansionThe trem-cel trial has been expanded to include patients diagnosed with myelodysplastic syndromes, which represents a significant increase in population.
Financial PerformanceVor ended 1Q24 with $107.5M in cash, which management anticipates will be sufficient to fund operations into the second half of 2025.
Bears Say
Financial HealthInvestor concerns over high rates of cash burn paired with early development stages.
Regulatory NewsNegative headline news for the cell therapy sector from regulatory agencies.
Stock PerformanceVor Biopharma's stock remains depressed and the company is currently trading near its enterprise value.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VOR FAQ
What was Vor Biopharma’s price range in the past 12 months?
Vor Biopharma lowest stock price was $0.90 and its highest was $3.48 in the past 12 months.
What is Vor Biopharma’s market cap?
Currently, no data Available
When is Vor Biopharma’s upcoming earnings report date?
Vor Biopharma’s upcoming earnings report date is Aug 08, 2024 which is 106 days ago.
How were Vor Biopharma’s earnings last quarter?
Vor Biopharma released its earnings results on May 09, 2024. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.378 by -$0.072.
Is Vor Biopharma overvalued?
According to Wall Street analysts Vor Biopharma’s price is currently Undervalued.
Does Vor Biopharma pay dividends?
Vor Biopharma does not currently pay dividends.
What is Vor Biopharma’s EPS estimate?
Vor Biopharma’s EPS estimate is -$0.42.
How many shares outstanding does Vor Biopharma have?
Vor Biopharma has 68,259,605 shares outstanding.
What happened to Vor Biopharma’s price movement after its last earnings report?
Vor Biopharma reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.378. Following the earnings report the stock price went down -5.525%.
Which hedge fund is a major shareholder of Vor Biopharma?
Among the largest hedge funds holding Vor Biopharma’s share is RA Capital Management. It holds Vor Biopharma’s shares valued at 54M.
---
Vor Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.36 (1379.34% Upside)
$14.36 (1379.34% Upside)
Blogger Sentiment
Bullish
VOR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 10.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 6.6%
Last 30 Days ▼ 6.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.01%
12-Months-Change
Fundamentals
Return on Equity
-68.07%
Trailing 12-Months
Asset Growth
-39.82%
Trailing 12-Months
Company Description
Vor Biopharma
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies.
---
VOR Stock 12 Month Forecast
Average Price Target
$14.36
▲(1379.34% Upside)
Technical Analysis
Crinetics Pharmaceuticals
―
Rocket Pharmaceuticals
―
Sarepta Therapeutics
―
Allogene Therapeutics
―
Best Analysts Covering VOR
1 Year
1 Year Success Rate
1/14 ratings generated profit
1 Year Average Return
-49.95%
reiterated a buy rating 7 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 7.14% of your transactions generating a profit, with an average return of -49.95% per trade.
---